


ETCTN Trials by Disease/Treatment Area: Solid Tumors with Specific Mutations



NOTE: ▼ Limited trial; not open ETCTN-wide

ETCTN Solid Tumors with Specific Mutations Trials (Open as of 3/10/2026)

| Protocol Number | Phase | Protocol Title |
|-----------------|-------|---|
| 10355 | I | A Phase I Study of DS-8201a in Combination with Olaparib in HER2-Expressing Malignancies |
| 10371 | II | A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients with Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage Response |
| 10528 | I | Phase 1 study of the POLq inhibitor Novobiocin in BRCA-mutant and other DNA damage repair-deficient solid tumors |
| 10527 | Ib | A Molecularly Driven Phase 1b Dose Escalation and Dose Expansion Study of the DNA-PK Inhibitor Peposertib (M3814) in Combination with the ATR Inhibitor M1774 |
| 10572 | I | A Phase 1 Trial Evaluating the Combination of Temozolomide and the Ataxia Telangiectasia and Rad3-Related Inhibitor M1774 |
| 10495 | I | Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination with Neratinib in Solid Tumors with HER2 Alterations |
| 10358 | I/Ib | Phase 1/1B Study of DS-8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial) |
| 10720 | Ib | Phase 1b study of Pidnarulex and Trastuzumab Deruxtecan in patients with HER2 expressing Solid Tumors |